109 results
Page 4 of 6
8-K
EX-99.1
6tptg0ne8 7f
12 Jun 20
Dosing expected to begin in Q2 2020 with first data in Q3 2020
12:18pm
8-K
EX-99.1
dpkp nm5s6tfh6s509
1 Jun 20
Other Events
4:40pm
8-K
EX-99.1
rl1gs40x0fa2 k7cl
26 May 20
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program
4:45pm
8-K
EX-99.1
2d7sh 6nd
20 May 20
Other Events
5:27pm
8-K
EX-99.1
56fbhc9
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-99.2
6i0zvn 9zing2ia0smyl
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-99.1
n206 cij88szjt21k3n
11 May 20
Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
4:58pm
8-K
EX-99.1
hrj9zb3cabbw
8 May 20
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
4:40pm
8-K
EX-99.1
a875gsakgl9y
29 Apr 20
Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19
8:44am
8-K
EX-99.1
m5xpmfj4
1 Apr 20
Partnering with University of Virginia Health and iTHRIV
4:41pm
8-K
EX-99.1
9uy runyjh6tfc
24 Mar 20
Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus
4:41pm
8-K
EX-99.1
k4bywrn5 qnmf
18 Mar 20
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
5:22pm
8-K
EX-99.2
oy1fj5kd 3xsnywl4e6m
18 Mar 20
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
5:22pm
8-K
EX-99.1
p945b1688ek
13 Jan 20
Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors
4:16pm
8-K
EX-99.2
oc9tvb15yiq5xel
13 Dec 19
Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
4:19pm
8-K
EX-99.1
xy8qsrxseb32c
13 Dec 19
Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
4:19pm
8-K
EX-99.1
4si397eo6awj
10 Dec 19
Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development Summit
4:25pm